Drugs / LY01005
LY01005
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05140512 | Feb → Sep 2021 | prostate cancer | Luye Pharma Group Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03450109 | Dec 2017 → Oct 2018 | prostate cancer | Luye Pharma Group Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06385847 | May 2024 → May 2025 | prostate cancer | The First Affiliated Hospital of Xiamen University | Unknown | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05110170 | Oct 2020 → Apr 2022 | breast cancer | Luye Pharma Group Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT04563936 | Jan 2020 → Mar 2021 | prostate cancer | Luye Pharma Group Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY01005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05110170 ↗ |
| Known as | Goserelin | “while the Goserelin microsphere (LY01005) 3.6 mg is administered every 28 days by intramuscular injection using a 21G injection needle (outer diameter 0.8 mm)” NCT06385847 ↗ |
| Known as | Goserelin acetate sustained-release microsphere injection | “LY01005 (Goserelin acetate sustained-release microsphere injection) is a modified gonadotropin-releasing hormone (GnRH) agonist injected monthly.” PMID 37010251 ↗ Apr 2023 |
| Route | Intramuscular | “One LY01005 3.6 mg gluteal IM injection.” NCT03450109 ↗ |